Verge Genomics Pivots to AI Platform Focus After Clinical Failure of Lead ALS Drug and Executive Exodus

AnotherAIThe drug failed.

According to reports,Verge GenomicsTheVRG50635In patients with Amyotrophic Lateral Sclerosis (ALS)1bThe efficacy during the period did not meet the standards,The clinical trial has been terminated.

The company stated that the full study results of the drug will be released in the first half of next year.

VRG50635ByVerge Genomics' AI Platform IdentifiesThe target is also the company's only clinical-stage drug.

But after the drug failed,Verge GenomicsAnnouncing the start of a business model shift, bybiotechShifting to a Cooperation-Oriented Business Model。

However, misfortunes never come singly, recently20MonthsIn,Verge GenomicsMost of the executives have left, including the Chief Financial Officer, Chief Scientific Officer, and Chief Medical Officer. Jane Rhodes, President and Chief Business OfficerLeft last year to join Verge GenomicsAstronauTxThe CEO.

Drug Failure, Executive Departures, Strategic Shift......Establishment10Year'sVergeWhere will the future lead?

Founded by Chinese Women

Verge GenomicsIn2015Launched in the year, FounderAlice Zhang(English name: Zhang XinliIs an American of Chinese descent.

Zhang Xin was born in Virginia to Chinese immigrant parents,SheInterested in biomedicine from a young age, after graduating from high school, she pursued an undergraduate degree in molecular biology at Princeton University and later a Ph.D. in neuroscience at the University of California, Los Angeles.

Verge GenomicsFounderAlice Zhang

In herIt seems that all these reasons are due to a lack of comprehensive understanding of the disease and failure to identify optimal molecular drug targets.

Based on these considerations,Verge GenomicsCreated a name called“All Humanity”（all-in-human) for drug discovery, they discarded the data derived from animal models in the past and chose to build their own database specifically targeting neurodegenerative diseases.

VergeBuilt over6800A human dataset of individual tissue samples (mainly brain and spinal cord), also including various data such as gene expression, genotyping, and patient characteristics, is one of the largest proprietary human brain tissue genomic datasets in this field.

With the help of artificial intelligence methods, the company inDNA Known connections between sequences, gene expression patterns, and diseases“Training”Dataset to learn how to find new, powerful biological associations in the dataset of interest.

AndVRG50635Based onVergeTheAIPlatform-based.

First, the company determinedPIKfyvePhosphoinositide kinase isALSNovel Targets in Patients，YesCancer, Viral Infections, and Neurodegenerative DiseasesAn important pathway.

PIKfyve as a Drug Target Signaling Pathway

Immediately following,VergeObtainedPIKfyveInhibitorVRG50635, the drug can restoreALS Neurons of the patient Endolysosomal function, and in ALS Efficacy has been demonstrated in multiple preclinical studies in relevant motor neuron degeneration models.

2022Year10Month, the drug entered clinical trials for the first timeInitiate human dosing.

Verge GenomicsThe platform and drugs have also drawn attention from Eli Lilly.

2021Year7Month,Verge Genomics Announced a partnership with Eli Lilly for a period of3 -year cooperation agreement, the two parties will jointly develop targetedALSInnovative therapies.

Verge Will receive2500 Million USD upfront payment, with a potential value of nearly7USD milestone payments and royalties.

Drug Failure, Company Turns to Verge Genomics

Development of TreatmentAmyotrophic Lateral Sclerosis (ALS)The drug is widely recognized as one of the most formidable challenges in the fields of neuroscience and pharmaceutical research and development.

In the past two decades, at least 50 ItemAbout ALSThe clinical trials of the therapy failed to show positive results. In the United States, only three drugs have been approved, and these drugs offer minimal benefits to patients.

ForVerge For them, it is an even greater gamble. BecauseVRG50635Is its only clinical asset.

Just recently, the company decided to terminateVRG50635The decision of the clinical trial was due to the lack of risk-benefit data.

The company had high expectations for the drug, pouring almost all resources into it, leaving no other candidate drugs entering the clinical trial stage.

ThereforeVergeAnnouncing the transformation,Will Focus on Its Artificial Intelligence PlatformAnd datasets, helpPartnership EnhancementDrugSuccess rate.

The founder said,This move has madeVergeCapable of continuously investing in its artificial intelligence, product, and engineering capabilities, resulting in a leaner cost structure and longer cash flow.

After all, the cost and risk of drug development are both too high.

Accompanying the failure of the core drug are the company's turbulent executive changes.

In the past20MonthsIn,VergeMost of the senior executives have left, including the Chief Financial Officer, Chief Scientific Officer, and Chief Medical Officer. The President and Chief Commercial OfficerJane Rhodes Left last year to join Verge GenomicsAstronauTxThe CEO.

The company's financial situation is also not optimistic.Verge Genomics' last round of financing was in 2021, when it received $98 million in Series B funding in December, with participation from Eli Lilly.

Fortunately, the company has a cooperation agreement with multinational pharmaceutical enterprises.

2023Year9Month,Verge GenomicsAnnouncement with AstraZeneca Rare Disease DivisionAlexionEstablish a four-year partnership to identify new drug targets.

As part of the agreement,VergeWill receive up to4200Million-dollar upfront payment, equity, and near-term payments. The company may also receive up to8.4USD milestone payments, as well as royalties on any resulting products.

For the company situation, the founderAlice ZhangIt is reported that the company will update its pipeline status and the latest personnel appointments early next year.

—END—

Recommended Reading